DAX ®9.632,52-3,68%TecDAX ®2.506,46-3,31%S&P FUTURE2.524,10-3,35%Nasdaq 100 Future7.568,50-3,61%
finanztreff.de

BUSINESS WIRE: Galderma Announces New England Journal of Medicine Publication from Phase 2 Study of Investigational Therapy Nemolizumab in Patients with Moderate to Severe Prurigo Nodularis

| Quelle: Business_Wire | Lesedauer etwa 4 min. | Text vorlesen Stop Pause Fortsetzen

MITTEILUNG UEBERMITTELT VON BUSINESS WIRE. FUER DEN INHALT IST ALLEIN DAS BERICHTENDE UNTERNEHMEN VERANTWORTLICH.

  • Results from Phase 2 study published in the New England Journal of Medicine.
  • Nemolizumab met the primary endpoint of a greater improvement in Peak Pruritus Numerical rating scale (PP-NRS) from baseline to Week 4 compared to placebo.
  • Nemolizumab was recently granted FDA Breakthrough Therapy Designation for the treatment of patients suffering from prurigo nodularis.

LAUSANNE, Switzerland (BUSINESS WIRE) 20.02.2020

Galderma today announced that The New England Journal of Medicine (NEJM) has published full results from the Phase 2 study of its investigational therapy nemolizumab in adult patients suffering from moderate-to-severe prurigo nodularis (PN).

PN is a rare, potentially debilitating, chronic skin condition with thick skin nodules covering large body areas and associated severe pruritus. It frequently leads to a severe quality of life impairment. Nemolizumab is a first-in-class investigational monoclonal antibody that blocks signaling of IL-31 that play a key role in the pathogenesis of PN. Nemolizumab’s safety and efficacy have not been fully evaluated by any regulatory authority.

In this study, 70 patients with moderate to severe PN and severe pruritus were randomized to receive subcutaneous nemolizumab 0.5 mg/kg every 4 Weeks from baseline to Week 8 or matching placebo injections (at weeks 0,4 and 8). Nemolizumab met the primary endpoint of a greater improvement in Peak Pruritus Numerical rating scale (PP-NRS) from baseline to Week 4 compared to placebo. The baseline PP-NRS was 8.4 in both groups. At week 4, in nemolizumab arm PP-NRS was reduced from baseline by 4.5 (53.0%) compared to 1.7 (20.2%) in placebo; P<0.001. All the other measures showed a significant difference in patients taking nemolizumab. At week 18 (10 weeks after the last dose), 38 percent of the patients who received nemolizumab were clear or almost clear of PN compared to 6 percent of the patients who received placebo; P=0.001. Nemolizumab was well tolerated and no imbalance in adverse events was observed between the two groups. The full publication is available at https://www.nejm.org/doi/full/10.1056/NEJMoa1908316

“Prurigo nodularis is known to have a profoundly negative impact on quality of life of patients, and despite significant unmet needs, there are currently no registered therapeutic options” said Dr Thibaud Portal, Global Head of Prescription medicines at Galderma. “The Phase 2 study results indicate that nemolizumab may have a key role to play for patients with moderate to severe prurigo nodularis. We are fully committed to test this drug further in Phase 3 studies and determined to bring solutions for patients suffering from prurigo nodularis.”

“The New England Journal of Medicine publication brings important attention to prurigo nodularis, where it has been very challenging for clinicians to take care of their patients in the absence of any registered therapy targeting prurigo nodularis” said Sonja Ständer, M.D., Center for Chronic Pruritus, Department of Dermatology, University of Münster, Germany and lead author of the NEJM paper. “We are encouraged by the consistent findings across this study and look forward to further clinical investigation with nemolizumab.”

In November 2019, the U.S. Food and Drug Administration granted Breakthrough Therapy Designation to the investigational therapy nemolizumab for the treatment of pruritus associated with PN. Galderma is actively preparing for the initiation of a Phase 3 pivotal program with nemolizumab in adult patients with PN in 2020.

About Nemolizumab

Nemolizumab, a first-in-class humanized monoclonal antibody, is directed against the IL-31 receptor alpha, which blocks signaling from IL-31. Nemolizumab, initially developed by Chugai Pharmaceutical Co., Ltd., was subsequently licensed to Galderma in 2016 – worldwide except Japan and Taiwan. Nemolizumab is an investigational agent under clinical development and its safety and efficacy have not been fully evaluated by any regulatory authority.

About Galderma

Galderma, the world's largest independent global dermatology company, was created in 1981 and is now present in over 100 countries with an extensive product portfolio of prescription medicines, aesthetics solutions and consumer care products. The company partners with health care practitioners around the world to meet the skin health needs of people throughout their lifetime. Galderma is a leader in research and development of scientifically-defined and medically-proven solutions for the skin. For more information, please visit www.galderma.com

Media Contact
Sébastien Cros
Head of Corporate Communications
media@galderma.com

Werbung

Das könnte Sie auch interessieren

Weitere Nachrichten

Quelle: Business_Wire
06:58 BUSINESS WIRE: Jack Ma Foundation and Alibaba Foundation Donate to Seven More Countries in Asia to Fight COVID-19
28.03. BUSINESS WIRE: C3.ai, Microsoft und führende Universitäten starten das C3.ai Digital Transformation Institute
27.03. BUSINESS WIRE: Diligent offre un accesso senza soluzione di continuità al Video conferencing su tutte le piattaforme dei Consigli di amministrazione aziendali per garantire riunioni virtuali sicure in un momento in cui la forza lavoro passa alla modalità.
27.03. BUSINESS WIRE: DeltaTrak meldet Verfügbarkeit von neuem berührungslosem Infrarot-Stirnthermometer zur Unterstützung der Coronavirus-Prävention
27.03. BUSINESS WIRE: Monument Re übernimmt GreyCastle Holdings Ltd und seine Tochtergesellschaften
27.03. BUSINESS WIRE: Sierra Metals kündigt 13-tägige Verlängerung der Aussetzung des Yauricocha-Minenbetriebs gemäß der von der Regierung angeordneten Verlängerung des Ausnahmezustands an, um die weitere Ausbreitung des COVID-19-Virus in Peru einzudämmen
27.03. BUSINESS WIRE: Der Blutfilter Affinity von ExThera wird zur Behandlung von COVID-19-Patienten eingesetzt
27.03. BUSINESS WIRE:  PTC stellt browserbasierte CAD-Plattform kostenlos für Lehre zur Verfügung
27.03. BUSINESS WIRE: XPRIZE reagiert auf COVID-19 mit Bildung einer globalen Allianz von Innovatoren, die unkonventionelle Lösungen für Pandemiegefahren finden sollen
27.03. BUSINESS WIRE: DeltaTrak annuncia il lancio di un nuovo termometro da fronte a infrarossi senza contatto per contribuire alla prevenzione dell’infezione da coronavirus
Rubrik: Finanzmarkt
11:32 VIRUS: Söder verteidigt Bayerns Maßnahmen in der Corona-Krise
11:31 Corona bremst Klimadiplomatie - Umweltministerin Schulze will gegenhalten
11:24 VIRUS: Ministerium erstellt Checkliste für Unternehmen in Corona-Not
11:23 Von der Leyen setzt trotz Corona-Krise weiter auf Klimaschutz
11:22 VIRUS: Bundeswehr zieht Soldaten aus dem Irak wegen Corona teilweise ab
10:35 VIRUS/ROUNDUP 3: Trump riegelt Corona-Hotspots nicht ab - mehr als 2000 Tote
10:35 VIRUS/ROUNDUP: Corona-Todesfälle nun in jedem Bundesland - 54 200 Infektionen
10:35 VIRUS/ROUNDUP: Mehr als 10 000 Corona-Tote in Italien - aber auch mehr Geheilte
10:35 VIRUS/ROUNDUP/Medienforscher: Corona-Krise verleiht Fake News hohe Verbreitung
10:34 ROUNDUP/Südkorea: Nordkorea testet wieder Rakete

News-Suche

Suchbegriff:

Aktuelle Videos

HSBC Trading TV

Werbung

Trading-Tipp

Börsen & Märkte

US-Marktüberblick

zur Mediathek
Werbung

Werbung
Diese Seite empfehlenschliessen
Interessant, oder?
Teilen Sie diese Seite auf Facebook oder Twitter
Wenn Sie auf die Teilen-Buttons klicken und sich bei den Betreibern einloggen, werden Daten an den jeweiligen Betreiber übermittelt. Bitte beachten Sie die Datenschutzerklärung.
Aktuelle Umfrageschliessen
Wie, glauben Sie, wird der DAX am Ende dieser Woche - KW 14 - stehen?
Jetzt abstimmen!
Alle Umfragen ansehen